Drug eluting stent coating with extended duration of drug release

A stent for placement at a vascular site for inhibiting restenosis at said injury site, comprising:

• a stent body formed from a plurality of filaments;
• a drug-release coating matrix composed of:
• (i) 80-98% weight percent parylene first main polymer;
• (ii) 1-19 weight percent of a second polyethylene glycol capped with diisocyante moiety, and (iii) an anti-neoinitimal or anti-restenosis agent;
• said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via a catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site;
• and
• said coating being effective to release said anti-neoinitimal or anti-restenosis agent of the matrix over an extended period of time.

A stent for placement at a vascular site for inhibiting restenosis at said injury site, comprising:

• a stent body formed from a plurality of filaments,
• a drug-release coating matrix composed of:
• (i) 80-98% weight percent polyurethane first main polymer;
• (ii) 1-19 weight percent of a second polyethylene glycol capped with diisocyante moiety, and (iii) an anti-neoinitimal or anti-restenosis agent;
• said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via a catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site;
• and
• said coating being effective to release said anti-neoinitimal or anti-restenosis agent of the matrix over an extended period of time.

A method for treating vascular injury site, comprising:

• delivering to the vascular injury site, an stent comprising;
• a stent body formed from a plurality of structural member,
• a drug-release coating matrix composed of:
• (i) 80-98% weight percent polystyrene, parylene or urethane first main polymer;
• (ii) 1-19 weight percent of a second polyethylene glycol capped with diisocyante moiety, and (iii) an anti-neoinitimal or anti-restenosis agent,
• said stent being expandable from a contracted condition in which the stent can be delivered to a vascular injury site via a catheter, and an expanded condition in which the stent coating can be placed in contact with the vessel at the injury site, and
• said coating being effective to release said anti-neoinitimal or anti-restenosis agent of the matrix over an extended period of time,
• expanding the stent at the vascular injury site, to bring the stent coating in contact with the vessel at the injury site.